Institutions / Deerfield Management Company, L.P. / Activity
Activity — Deerfield Management Company, L.P.
112 moves.
| Date | Action | Company | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|
| Q1 2026 as of | Exit | Phreesia, Inc. Common stock | $-33.82M | -2.0M -100.00% | 0 | medium |
| Q1 2026 as of | New | BioMarin Pharmaceutical Inc Common stock | $48.10M | +852K | 851,556 0.72% of portfolio | medium |
| Q1 2026 as of | Trim | Revolution Medicines, Inc. Common stock | $-58.12M | -598K -20.65% | 2,297,000 3.33% of portfolio | high |
| Q1 2026 as of | Add | Inspire Medical Systems, Inc. Common stock | $61.76M | +1.2M +79.51% | 2,703,238 2.08% of portfolio | high |
| Q1 2026 as of | Add | Xenon Pharmaceuticals Inc. Common stock | $62.43M | +1.1M +198.09% | 1,615,696 1.40% of portfolio | high |
| Q1 2026 as of | New | 372303206 Common stock | $66.06M | +2.5M | 2,462,000 0.98% of portfolio | high |
| Q1 2026 as of | Trim | Neurocrine Biosciences Inc Common stock | $-75.66M | -574K -48.49% | 610,000 1.20% of portfolio | high |
| Q1 2026 as of | New | Pfizer Inc Common stock | $85.36M | +3.0M | 3,040,000 1.27% of portfolio | high |
| Q1 2026 as of | New | Dianthus Therapeutics, Inc. Common stock | $85.58M | +1.0M | 1,019,813 1.28% of portfolio | high |
| Q1 2026 as of | New | Syndax Pharmaceuticals Inc Common stock | $88.30M | +3.8M | 3,779,900 1.32% of portfolio | high |
| Q1 2026 as of | New | Indivior Pharmaceuticals, Inc. Common stock | $94.42M | +3.1M | 3,097,790 1.41% of portfolio | high |
| Q1 2026 as of | Exit | G4766E116 Common stock | $-121.74M | -3.4M -100.00% | 0 | high |